Efficacy and Tolerability of a Bilberry Extract in Volunteers With Impaired Twilight and Night Vision
Phase 2
Completed
- Conditions
- Healthy
- Interventions
- Drug: Anthocyan capsulesDrug: Placebo
- First Posted Date
- 2014-07-18
- Last Posted Date
- 2014-07-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 195
- Registration Number
- NCT02194127
Safety, Tolerability and Pharmacokinetics of Increasing Doses of BIBN 4096 BS in Healthy Male and Female Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: BIBN 4096 BS - in single rising dosesDrug: Placebo
- First Posted Date
- 2014-07-18
- Last Posted Date
- 2014-07-23
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 32
- Registration Number
- NCT02194335
Comparison of Safety and Efficacy of COMBIVENT HFA to COMBIVENT (CFC) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Phase 3
Terminated
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2014-07-18
- Last Posted Date
- 2014-07-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 360
- Registration Number
- NCT02194205
Safety, Tolerability and Pharmacokinetics After Administration of Increasing Dose of BIBN 4096 BS in Healthy Male and Female Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: BIBN 4096 BS - in single rising dosesDrug: Placebo
- First Posted Date
- 2014-07-18
- Last Posted Date
- 2014-07-23
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 38
- Registration Number
- NCT02194322
Investigation of the Metabolism and Pharmacokinetics of Ambroxol in Healthy Male Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: [14C]-cyclohexane ambroxol oral solutionDrug: [14C]-benzyl ambroxol oral solution
- First Posted Date
- 2014-07-18
- Last Posted Date
- 2014-07-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 12
- Registration Number
- NCT02194257
Surveillance of Patients With Suspected Acute Myocardial Infarction That Receive Early Inhospital Thrombolysis With Metalyse
- First Posted Date
- 2014-07-18
- Last Posted Date
- 2014-07-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 351
- Registration Number
- NCT02194153
Relative Bioavailability of Ambroxol Hydrochloride Lozenge in Comparison to Ambroxol Hydrochloride Syrup (Mucosolvan®) in Healthy Female and Male Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-07-18
- Last Posted Date
- 2014-07-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 20
- Registration Number
- NCT02194296
Safety, Tolerability and Pharmacokinetics of Inhalative Administration of BIBN 4096 BS in Healthy Male and Female Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: BIBN 4096 BS - in single rising dosesDrug: Placebo
- First Posted Date
- 2014-07-18
- Last Posted Date
- 2014-07-23
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 48
- Registration Number
- NCT02194777
Study to Evaluate Safety, Tolerability and Pharmacokinetics of Increasing Repeated Oral Doses of Ambroxol Lozenges in Healthy Male Volunteers
- First Posted Date
- 2014-07-18
- Last Posted Date
- 2014-07-23
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 34
- Registration Number
- NCT02194283
Pharmacokinetic Properties of Nevirapine Extended Release Tablets When Administered Orally in Healthy Male Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: Nevirapine, low doseDrug: Nevirapine, high dose
- First Posted Date
- 2014-07-18
- Last Posted Date
- 2014-07-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 48
- Registration Number
- NCT02194218